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Background: Chronic rhinosinusitis (CRS) is a highly prevalent inflammatory disease with significant impacts on
patient quality of life and daily productivity. Evaluating the volume of research on CRS, relative to similar chronic
diseases, may provide insight into current disparities in research prioritization.
Methods: A systematic review was performed using Ovid MEDLINE (R) (1970 – December 31st, 2014) to define
the volume of research publications for CRS, asthma, and diabetes mellitus (DM). Primary outcomes were overall
volume of research publications and volume of publications per year. A subgroup analysis was performed using
chi-square (χ2) omnibus test with 2×3 contingency tables to identify significant differences in the proportion of
total randomized controlled trials, systematic reviews, meta-analyses, and economic evaluation publications
between CRS, asthma, and DM groups.
Results: There were substantial disparities in the volume of research published over the last 45 years for CRS (n = 7,962),
asthma (n = 136,652), and DM (n = 337,411). Although the volume of research for CRS in increasing, the disparities in
the annual publication volumes between CRS, asthma, and DM appeared consistent over the last 45 years.
Conclusions: Outcomes from this review have demonstrated a large disparity in the volume of published research for
CRS compared to asthma and DM. Given the similarities in prevalence rates, impact on quality of life and economic
burden, the relative under supply of CRS research should prompt efforts to increase research prioritization for this
chronic disease.
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The advancement of medical knowledge with subsequent
translation into real world improvements is a key mandate
for several stakeholders in health care [1-3]. Peer-reviewed
publication is an essential vehicle to share newly acquired
knowledge, and without publication of high quality re-
search, advancements in the quality of care will be limited.
Since there are scarce resources to support medical re-
search, it is important to prioritize resources toward the
highest impact diseases, however, due to the large number
of different stakeholders involved in health care, research
prioritization is a very complex process [4]. Several factors
influence research priority setting, however, one important
factor is the estimated burden of disease [5-7].Correspondence: Lukerudmik@gmail.com
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unless otherwise stated.Chronic rhinosinusitis (CRS) not only represents one
of the most prevalent chronic diseases in developed
countries [8] but also represents a substantial burden of
disease on patient quality of life [9], productivity [10], and
health care spending [11]. Based on the best available
evidence, the prevalence of CRS in North America and
Europe likely falls within the range of 5% and 12% [12-14]
which rivals and potentially exceeds that of other common
chronic diseases such as asthma and diabetes mellitus
(DM) (Table 1) [12,15-18]. If research prioritization accur-
ately reflects burden of disease, then the volume and qual-
ity of publications should be somewhat similar between
diseases with similar burden of disease.
The primary objective of this review is to evaluate how
the volume of research publications for CRS has changed
over the last 45 years and compare the volume of research
to asthma and DM. The secondary objective is to evaluate
the differences in high-quality publications between eachis an Open Access article distributed under the terms of the Creative Commons
rg/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Table 1 Geographic prevalence rates per chronic disease
Chronic disease Prevalence
Canada US Europe/UK Mean
CRS 5.7% [13] 12.1% [12] 10.9% [14] 9.6%
Asthma 7.9% [15] 8% [12] 3.8% [16] 6.6%
DM 6.6% [17] 8.6 [12] 6.4% [18] 7.2%
US, United States; UK, United Kingdom; CRS, chronic rhinosinusitis; DM,
diabetes mellitus.
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identify potential disparities in research output for CRS,
compared to similar chronic diseases, which may be used
to improve future research priority setting.
Methods
The three comparator groups in this review include:
CRS, asthma, and DM (both type I and II). Asthma and
DM were chosen as comparators due to their similar
chronic disease state (often requiring life-long medical
therapy) as well as their similar prevalence rates [12-18]
and impact on quality of life [9,19,20]. A literature
search was performed in December 2014 using Ovid
MEDLINE (R) (1970 - December 2014) to define the
volume of research publications for CRS, asthma, and
DM. The following search terms were used to identify
published literature for CRS (terms: ‘chronic’ AND
‘*sinusitis’), asthma (term: ‘asthma’), and DM (terms:
‘diabetes’ AND ‘mellitus’). An unlimited truncation strat-
egy (placement of *) was used to capture all variations of
key disease related terms.
After the overall volumes of publications were obtained,
limitations for randomized controlled trials (RCTs), sys-
tematic reviews (SRs), and meta-analyses (MAs) were
applied to separate the overall volume of publications
into sub groups. The National Institute for Health
Research Economic Evaluation Database (NHS EED)
was searched using the same key terms to identify the
volume of economic evaluations (EEs) published for
each chronic disease. A chi-square (χ2) omnibus test
with 2x3 contingency tables was performed to identify
significant differences in the proportion of total RCT,
SR, MA, and EE publications between CRS, asthma,
and DM groups. Significant global tests were followedTable 2 Publications per chronic disease between 1970 -2014
Chronic disease Crude number
of publications
RCTs (% of total
publications)
CRS 7,962 296 (3.7%)
Asthma 136,652 8,192 (6.0%)
DM 337,411 13,633 (4.0%)
p-value χ2 = 862.4; p < 0.001
CRS, chronic rhinosinusitis; RCTs, randomized controlled trials; SRs, systematic reviewwith bivariate subgroup testing was complete to identify
differences between CRS, asthma, and DM groups.
Results
Volume of publications
The literature review demonstrated large disparities in
volume of publications between CRS, asthma, and DM
(Table 2). There were 1,171 articles that overlapped with
both CRS and asthma, which represented 15% of the
CRS volume and 0.9% of the asthma volume. When
evaluating the proportion of research dedicated to high-
level evidence (ie. RCTs, SRs, MAs, and EEs), there were
differences in the proportions of RCTs, SRs, and MAs
published between groups (all <0.018)(Table 2).
The bivariate analysis demonstrated that for the RCTs,
there is a significant difference between CRS and asthma
(3.7% vs. 6.0%; χ2 = 70.6; p < 0.001) as well as asthma and
DM (6.0% vs. 4.0%; χ2 = 845.8; p < 0.001), but not any
significant difference between the CRS and DM groups
(3.7% vs. 4.0%; χ2 = 2.1; p = 0.148). This indicated that
the asthma literature produced the largest proportion of
RCTs compared to CRS and DM.
For SRs, there is a significant difference between CRS
and asthma groups (2.9% vs. 2.5%; χ2 = 4.6; p = 0.032) as
well as CRS and DM groups (2.9% vs. 2.1%; χ2 = 19.4;
p < 0.001) and asthma and DM groups (2.5% vs. 2.1%;
χ2 = 51.4; p < 0.001). This indicates that the CRS litera-
ture contained the largest proportion of SRs followed
by asthma and then DM.
For MAs, there is no significant difference between CRS
and asthma groups (0.5% vs. 0.5%; χ2 = 0.5; p = 0.828),
CRS and DM groups (0.5% vs. 0.6%; χ2 = 0.9; p = 0.334)
but there is a significant difference between asthma and
DM groups (0.5% vs. 0.6%; χ2 = 7.4; p = 0.007). This indi-
cates that the DM and CRS literature produced similar
proportions of MAs to each other but a larger proportion
compared to asthma.
For EEs, there is a significant difference between CRS
and asthma groups (0.1% vs. 0.2%; χ2 = 4.9; p = 0.026),
as well as between the CRS and DM groups (0.1% vs.
0.2%; χ2 = 4.1; p = 0.043), however no significant differ-
ence between the asthma and DM groups (0.2% vs.
0.2%; χ2 = 1.2; p = 0.279). This indicates that the DM andSRs (% of total
publications)
MAs (% of total
publications)
EEs (% of total
publications)
227 (2.9%) 42 (0.5%) 8 (0.1%)
3,370 (2.5%) 746 (0.5%) 299 (0.2%)
7,177 (2.1%) 2,068 (0.6%) 685 (0.2%)
χ2 = 65.2; p < 0.001 χ2 = 8.0; p = 0.018 χ2 = 5.6; p = 0.062
s; MAs, meta-analyses; EE, economic evaluations.
Figure 1 Publications per year. (A) DM vs. Asthma vs. CRS; (B) Asthma vs. CRS; (C) CRS alone.
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each other but a larger proportion compared to CRS.
Changes in publication volume with time
When evaluating the proportion of research publications
per year (between 1970 and 2014), the disparities in
volume appear to be consistent over time between CRS,
asthma, and DM (Figure 1A and B). There appears to be
an exponential increase in the volume of CRS-related
publications over the last 15 years (Figure 1C).
Discussion
Measuring and reporting of medical outcomes using
research publications is an important factor to drive
quality improvement in health care [21,22]. This review
has demonstrated a large disparity in the volume of
research publications between CRS, asthma, and DM.
Despite having similar prevalence rates, CRS had 6% and
2% of the publication volume compared to asthma and
DM, respectively. Although there were minor differences
in the proportion of high quality publications (RCTs,
SRs, MAs, and EEs), the tremendous gap in overall
number of publications is concerning given the fact that
CRS results in similar negative impacts on quality of life
[9] and economic burden [10,11] to that of asthma and
DM (Table 3).
Research priority setting has focused on burden of
disease to justify resource allocation [5,6]. However,
without adequate support and awareness, certain med-
ical conditions may be inappropriately under-researched
relative to its burden of disease on society. Based on
the outcomes from this study, CRS is an example of a
highly prevalent chronic condition that is being under-
researched given its well-documented negative impacts.
This raises the question of: “Why is CRS being under-
researched given its large burden of disease on society?”.
Although the answer to the above question is likely
multi-factorial, one important factor may be the general
lack of awareness of CRS in the medical community, as
was discussed in a recent article by Tan et al. titled
“Chronic Rhinosinusitis: The Unrecognized Epidemic”Table 3 Utility, DALY, and economic comparisons between CR
Chronic disease Health state utility (SF-6D derived) Disability
CRS 0.65 [9] Not define
Asthma 0.70 [19] b0.009 [24]
c0.027 [24]
DM 0.68 [20] 0.015 [26]
(Note: all values were adjusted with an inflation calculator to reflect 2014 USD).
DALY, disability adjusted life years; CRS, chronic rhinosinusitis; DM, diabetes mellitu
aThis indirect cost reflects patients with refractory CRS who were recruited from a t
patients with CRS.
bThis is the disability weight for ‘controlled asthma’.
cThis is the disability weight for ‘partially controlled asthma’.
dThis indirect cost reflects patients with severe asthma and likely overestimates the[28]. This is highlighted by a recent multi-national study
intended to quantify the burden of disease for 291 medical
conditions around the globe [29]. This study evaluated
common chronic diseases such as DM, asthma, coronary
artery disease, hypertension, neck pain, osteoarthritis
and migraine but failed to include CRS on the list of
conditions. The omission of CRS from an international
evaluation of burden of disease highlights the lack of
awareness for this condition.
Despite CRS failing to be included in two recent
multi-national studies quantifying burden of disease
[29,30], the high prevalence rate should provide a strong
incentive to include CRS in future discussions on research
prioritization. The lowest estimate of CRS prevalence is
5%, which came from a 2003 Canadian survey of 73,364
people who were asked “if they have sinusitis diagnosed
by a health professional”. Although asking patients for
physician diagnosed CRS increases the sensitivity by
reducing false positives, it will likely result in an under-
estimate due to missing people who have not sought
medical care for their CRS. This is in contrast to the
highest estimate of 12% from the 2014 US National
Health Interview Survey (NHIS) which asked patients if
they had ‘sinusitis’ rather then asking specifically about
whether or not a physician diagnosed their sinusitis.
The estimate from the US study will be more specific
by increasing the true negative rate, however, it may
include false positives such as patients with acute
rhinosinusitis or other non-sinus diseases that mimic
CRS such as migraines. In 2011 the Global Allergy and
Asthma European Network (GA2LEN) applied a strict
symptom-based approach using the European Position
Paper on Rhinosinusitis and nasal Polyps (EP3OS) diagnos-
tic criteria to estimate the prevalence of CRS in Europe.
This study surveyed 57,128 people from 12 European
countries and demonstrated the mean prevalence of CRS
was 10.9% (range: 6.9 to 27.1%). Using the strict EP3OS
symptom-based diagnostic criteria will reduce the false
positive rate while maximizing the true negative rate thus
increasing both the specificity and sensitivity of the CRS
prevalence. Despite the inherent challenges with providingS, asthma and DM
weight Annual direct health care cost Annual indirect cost
d $3,143/patient [23] a$10,500/patient [10]
$4,081/patient [25] d$5,846/patient [25]
$7,900/patient [27] $3,920/patient [27]
s; SF, short-form.
ertiary level centre and likely over-estimates the mean indirect cost for all
mean indirect cost for all patients with asthma.
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CRS in North America and Europe likely falls between 5%
and 12% which is similar to asthma and DM (Table 1).
In addition to overall prevalence, the associations be-
tween CRS and reduced quality of life and economic
burden are other important factors to consider. When
comparing health state utility values of patients living
with CRS, asthma and DM, the values appear to be similar
when using the SF-6D instrument (Table 3). Furthermore,
when considering the direct and indirect costs of each of
these chronic diseases, DM appears to have larger direct
health care costs compared to CRS, however, the indirect
cost of refractory CRS is substantially higher then DM.
The differences between direct and indirect costs of CRS
and DM may reflect increased public awareness of DM
resulting in patients seeking more medical therapy. As
opposed to CRS, which may not have the same public or
physician awareness and result in a substantial proportion
of the population failing to receive appropriate medical
treatments. The disparities in direct and indirect health
care costs between CRS, asthma, and DM warrant future
research.
A second potential reason for the disparity in publi-
cation volume may include a perception that CRS is a
sub-specialty topic, which makes it challenging to publish
research in higher impact journals that have a broader
audience. This perception may deter basic science, clinical,
or pharmacoeconomic researchers from adopting CRS as
their academic focus despite tremendous opportunities to
provide meaningful contributions. Thirdly, as opposed to
CRS, untreated cases of asthma and DM may result in
mortality. Although CRS has similar QoL reductions and
indirect costs, the difference in mortality risk may have
lead researchers to focus on asthma and DM. Lastly, there
are fewer rhinologists to perform CRS research compared
to the number of general internists, endocrinologists, or
pulmonologists, who perform research for asthma and
DM. However, given that CRS represents 1-2% of primary
care physician visits [23,31], is associated with comorbid
allergies in 20 to 60% of cases [32,33], and is commonly
associated with asthma outcomes [34,35], CRS research
should not only be conducted by rhinologists, but by
primary care physicians, allergists, pulmonologists, and
general internists. Efforts to increase awareness for the
importance of CRS to these medical specialties may help
reduce the disparity in publications
This article was intended to evaluate the overall dis-
parities in publication volume between CRS, asthma,
and DM. One limitation of this study is the inclusion of
one biomedical database (Ovid MEDLINE) which may
result in missing certain publications from each category
of chronic disease. However, when the EMBASE data-
base was included in the initial search it yielded the
same proportion of publication volume, with CRScontaining 2% and 6% of the total publication volume as
DM and asthma, respectively. Thus, to keep the search
strategy and outcomes simple and reproducible, one
database was searched to highlight the disparities in
publication volume.
Conclusion
This review has demonstrated a large disparity in the
volume of published research for CRS compared to
asthma and DM. Given the similarities in prevalence
rates, impact on quality of life and economic burden, the
relative under supply of research should prompt efforts
to improve research prioritization for CRS. Future
research should not only begin to elucidate factors
contributing to this gap in research volume, but also
begin to develop innovative strategies to increase disease
awareness for the importance of CRS on population
health.
Competing interests
The author declares the he has no competing interests.
Received: 2 January 2015 Accepted: 13 February 2015
References
1. Canadian Institutes of Health Research (CIHR). Mandate. http://www.cihr-irsc.
gc.ca/e/7263.html. Accessed Jan.2, 2015.
2. National Institutes of Health (NIH). Mission Statement. http://www.nih.gov/
about/mission.htm. Accessed Jan.2, 2015.
3. National Institute for Clinical Excellence (NICE). http://www.nice.org.uk/
about/what-we-do. Accessed Jan.2, 2015.
4. Fleurence RL. Setting priorities for research: a practical application of
‘payback’ and expected value of information. Health Econ. 2007;16
(12):1345–57.
5. Fleurence RL, Torgerson DJ. Setting priorities for research. Health Policy.
2004;69(1):1–10.
6. Gross CP, Anderson GF, Powe NR. The relation between funding by the
National Institutes of Health and the burden of disease. N Engl J Med.
1999;340(24):1881–7.
7. Lamarre-Cliche M, Castilloux AM, LeLorier J. Association between the
burden of disease and research funding by the Medical Research Council of
Canada and the National Institutes of Health. A cross-sectional study. Clin
Invest Med. 2001;24(2):83–9.
8. Halawi AM, Smith SS, Chandra RK. Chronic rhinosinusitis: epidemiology and
cost. Allergy Asthma Proc. 2013;34(4):328–34.
9. Soler ZM, Wittenberg E, Schlosser RJ, Mace JC, Smith TL. Health state utility
values in patients undergoing endoscopic sinus surgery. Laryngoscope.
2011;121(12):2672–8.
10. Rudmik L, Smith TL, Schlosser RJ, Hwang PH, Mace JC, Soler ZM.
Productivity costs in patients with refractory chronic rhinosinusitis.
Laryngoscope. 2014;124(9):2007–12.
11. Bhattacharyya N. Incremental health care utilization and expenditures for chronic
rhinosinusitis in the United States. Ann Otol Rhinol Laryngol. 2011;120(7):423–7.
12. Blackwell DL, Lucas JW, Clarke TC. Summary health statistics for U.S. adults:
national health interview survey, 2012. Vital and health statistics. Series 10,
Data from the National Health Survey. Feb 2014(260):1–161.
13. Chen Y, Dales R, Lin M. The epidemiology of chronic rhinosinusitis in
Canadians. Laryngoscope. 2003;113(7):1199–205.
14. Hastan D, Fokkens WJ, Bachert C, Newson RB, Bislimovska J, Bockelbrink A,
et al. Chronic rhinosinusitis in Europe–an underestimated disease. A GA(2)
LEN study. Allergy. 2011;66(9):1216–23.
15. Prevalence of Asthma. Statistics Canada. 2014; http://www.oecd-ilibrary.org/
social-issues-migration-health/health-at-a-glance-europe-2012/asthma-and-
copd-prevalence_9789264183896-19-en. Accessed Jan.2, 2015.
Rudmik Journal of Otolaryngology - Head and Neck Surgery  (2015) 44:11 Page 6 of 616. OECD. Asthma Prevalence in Europe. 2014; http://www.oecd-ilibrary.org/
social-issues-migration-health/health-at-a-glance-europe-2012/asthma-and-
copd-prevalence_9789264183896-19-en. Accessed Jan.2, 2015.
17. Prevalence of Diabetes Mellitus. Statistics Canada. 2014; http://www.statcan.
gc.ca/tables-tableaux/sum-som/l01/cst01/health54b-eng.htm. Accessed
Jan.2, 2015.






19. Joore M, Brunenberg D, Nelemans P, Wouters E, Kuijpers P, Honig A, et al.
The impact of differences in EQ-5D and SF-6D utility scores on the
acceptability of cost-utility ratios: results across five trial-based cost-utility
studies. Value Health. 2010;13(2):222–9.
20. Kontodimopoulos N, Pappa E, Papadopoulos AA, Tountas Y, Niakas D.
Comparing SF-6D and EQ-5D utilities across groups differing in health
status. Qual Life Res Int J Qual Life Asp Treat Care Rehab. 2009;18(1):87–97.
21. Berwick DM, James B, Coye MJ. Connections between quality measurement
and improvement. Med Care. 2003;41(1 Suppl):I30–8.
22. Wolpert AJ. For the sake of inquiry and knowledge–the inevitability of open
access. N Engl J Med. 2013;368(9):785–7.
23. Bhattacharyya N, Orlandi RR, Grebner J, Martinson M. Cost burden of
chronic rhinosinusitis: a claims-based study. Otolaryngology–head and neck
surgery : official journal of American Academy of Otolaryngology-Head and
Neck. Surgery. 2011;144(3):440–5.
24. WHO. Disability weights 2010. http://ghdx.healthdata.org/record/global-
burden-disease-study-2010-gbd-2010-disability-weights. Accessed Jan. 2, 2015.
25. Cisternas MG, Blanc PD, Yen IH, Katz PP, Earnest G, Eisner MD, et al. A
comprehensive study of the direct and indirect costs of adult asthma.
J Allergy Clin Immunol. 2003;111(6):1212–8.
26. WHO. Disability weights 2004. http://www.who.int/healthinfo/
global_burden_disease/GBD2004_DisabilityWeights.pdf. Accessed Jan.2, 2015.
27. Yang W, Dall TM, Halder P, Gallo P, Kowal SL, Hogan PF. Economic costs of
diabetes in the U.S. in 2012. Diabetes Care. 2013;36(4):1033–46.
28. Tan BK, Kern RC, Schleimer RP, Schwartz BS. Chronic rhinosinusitis: the
unrecognized epidemic. Am J Respir Crit Care Med. 2013;188(11):1275–7.
29. Murray CJ, Vos T, Lozano R, Naghavi M, Flaxman AD, Michaud C, et al.
Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21
regions, 1990–2010: a systematic analysis for the Global Burden of Disease
Study 2010. Lancet. 2012;380(9859):2197–223.
30. WHO. Global Health Observatory. 2014; http://www.who.int/gho/
mortality_burden_disease/daly_rates/en/. Accessed Jan. 2, 2015.
31. Sharp HJ, Denman D, Puumala S, Leopold DA. Treatment of acute and
chronic rhinosinusitis in the United States, 1999–2002. Arch Otolaryngol
Head Neck Surg. 2007;133(3):260–5.
32. Schlosser RJ. The pathophysiology of chronic rhinosinusitis. Int Forum
Allergy Rhinol. 2014;4(3):169–70.
33. Wilson KF, McMains KC, Orlandi RR. The association between allergy and
chronic rhinosinusitis with and without nasal polyps: an evidence-based
review with recommendations. Int Forum Allergy Rhinol. 2014;4(2):93–103.
34. Frieri M. Asthma linked with rhinosinusitis: An extensive review. Allergy
Rhinol (Providence). 2014;5(1):41–9.
35. Vashishta R, Soler ZM, Nguyen SA, Schlosser RJ. A systematic review and
meta-analysis of asthma outcomes following endoscopic sinus surgery for
chronic rhinosinusitis. Int Forum Allergy Rhinol. 2013;3(10):788–94.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
